
Why Great Science Doesn't Sell Itself - Fixing Clinical Research's Commercial Blind Spot
Episode 58
Pavel Trofimov spent roughly 15 years in international B2B sales across complex technical markets before moving into clinical research — where he noticed something the industry treats as normal. Founders, scientists and operational leaders were doing the delivery and the business development themselves. In most other regulated industries, that commercial work sits with a dedicated team. That gap became Lab-2-Business (L2B). Pavel's mission, in his own words: to help excellent scientific and technological companies be as deliberate about winning business as they are about delivering it. In this episode he unpacks the imbalance at the heart of clinical research — delivery machines built to be precise and never make mistakes, with almost no one positioned to make the value clear and turn it into revenue. He's sharp on why founder-led growth hits a ceiling, why he refuses "twin mandates" (so he never becomes the networking "head that changes its body" at every conference), and why he rejects the word "fractional" altogether — he embeds as an extended team member, aligned on scope and outcomes, in it for the long run. The conversation's most provocative turn is on AI-native startups. Pavel argues they face a harder sell than anyone: they're not selling a product into the clinical trial ecosystem, they're selling behaviour change — convincing people to change how they work, measure and invoice.
Publisher
Adam Walker’s Pharma Prescribed Podcast
Link
pharmaprescribed.podbean.com/e/why-great-science-doesnt-sell-itself-fixing-clinical-researchs-commercial-blind-spot/
Published
October 6, 2026
Duration
37 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Adam Walker
Adam Walker’s Pharma Prescribed Podcast
@adamwalkerspharmaprescribedp
#sciencedoesntsell #fixingclinicalresearchs #lifesciences #management
